Breakthrough in Breast Cancer Detection to be Addressed in Conference Call; Open Line Conference Call on Wednesday, Oct. 14, at 4:15 p.m. EDT.RENO, Nev.--(BW HealthWire)--Oct. 8, 1998--In the spirit of National Breast Cancer Awareness Month Breast Cancer Awareness Month is an annual international health campaign organized by major breast cancer charities every October to increase awareness of the disease and to raise funds for research into its cause, prevention and cure. , Lifeline BioTechnologies (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB:LBTI LBTI Left Belt Tensioner Igniter ) will address its breakthrough in breast cancer detection, through its proprietary product First Warning(tm). The Company has developed a non-invasive, pain-free test for detecting the formation of extremely early stage breast lesions, particularly in younger women. Dr. Kevin Buckman, Lifelines' CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. and Jim Holmes, Lifelines' CFO See Chief Financial Officer. will be available to discuss the latest company developments and to present a long-term strategic outlook for Lifeline BioTechnologies as part of an "open line" teleconference scheduled for Wednesday Oct. 14, beginning shortly after the market close at 4:15 p.m. EDT EDT abbr. Eastern Daylight Time EDT Eastern Daylight Time EDT n abbr (US) (= Eastern Daylight Time) → hora de verano de Nueva York EDT (3:15 p.m. Central/2:15 p.m. Mountain/1:15 p.m. Pacific). Among the topics to be addressed by Dr. Buckman will be Lifeline's recent advancements as well as comparisons with other breast cancer detection methods, including technology from Trex Medical Corporation (Amex: TXM TXM Thixomolding TXM Transaction Management TXM Technology Transition Model ) and Computerized Thermal Imaging, Inc. (OTC BBB BBB A medium grade assigned to a debt obligation by a rating agency to indicate an adequate ability to pay interest and repay principal. However, adverse developments are more likely to impair this ability than would be the case for bonds rated A and above. :COII). All current and prospective shareholders, institutional portfolio managers, investment bankers, securities analysts, members of the brokerage community, representatives of the trade and general business media, and other interested parties are welcome to participate in this conference call. To take part in the teleconference, participants must register through M&A West at 650/588-2678 or send in a request on Lifeline BioTechnologies' web site, www.lbti.com. Lifeline BioTechnologies, Inc. (Lifeline) has developed a non-invasive test for early breast cancer detection. The test is incorporated into a proprietary product called First Warning(tm). In preliminary pilot studies, First Warning(tm) demonstrated great promise in detecting formation of extremely early stage breast lesions, particularly in younger women. The second product division under Lifeline BioTechnologies is a line of nutritional food supplements packaged and sold under the tradename NATURE'S CREATIONS. These supplements are marketed and directed towards people afflicted with degenerative diseases that are commonly found in the aging population. These diseases include cancer (breast, colon and prostate) cardiovascular, osteoporosis and mental alertness. Financial Statements in this press release other than historical facts are "forward-looking" statements with the meaning of section 27A of the Securities Act of 1933, section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The Company intends that such statements about the Company's future expectations, including future revenues and earnings, and all other forward-looking statements are subject to the safe harbors created thereby. Since these statements (future operational results and sales) involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion